Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease

NCT00685373 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

166

Enrollment

INDUSTRY

Sponsor class

Conditions

Cryopyrin-Associated Periodic Syndromes
Familial Cold Autoinflammatory Syndrome
Muckle Wells Syndrome
Neonatal Onset Multisystem Inflammatory Disease

Interventions

DRUG: Canakinumab (ACZ885)

Sponsor

Novartis